Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT802 in Relapsing/Refractory Multiple Sclerosis
NCT07748637Phase 1Not yet recruiting
- Sponsor
- Daishi Tian
- Start
- Oct 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT802 in multiple sclerosis (MS), sponsored by Daishi Tian. Primary endpoints: Proportion of participants experiencing dose limiting toxicity at 28 days and Adverse Events at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
GT802
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07748637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748637.